arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

TG THERAPEUTICS, INC.

TGTX
$57.95 ▼ -3.73 (-6.04%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
82 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
70
Health
Good
Bullish
auto_awesome

Analytical Summary

TG THERAPEUTICS, INC. shows strong fundamentals with top-quartile Return on Common Equity (%) and Profit Margin (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $8.2B
Dividend Yield —
Revenue Growth 70.3% →
Op. Margin 9.0% ↘
ROIC 1.2% ↘
FCF / Share $0.27 ↗
Trailing P/E 1159.0x
Price / Book 14.7x
FCF Yield 0.5%
Debt / Equity 1.23
info Valuation on last close. End-of-day price, Nov 5, 2026.

82-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$240.34M
↑ +70.3% —
Net Income Profit after all expenses
$19.78M
↑ +290.8% —
Operating Margin Operating profit as % of sales
9.0%
↓ -46.9% 75th
FCF / Share Free cash flow per share
$0.27
↑ +321.3% —
Long-Term Debt Long-term obligations
$745.39M
— 0.0% —
trending_up

Bullish Indicators

  • Operating Margin (%)Operating Margin (%) is in the top quartile
  • Profit Margin (%)Profit Margin (%) is in the top quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability ↑
64
Returns
98
Financial Health ↓
66
Cash Quality
20

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 17 years · 82 quarters